Spyre Therapeutics, Inc. — Form 10-Q
Filed August 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
CEO Cameron Turtle and CFO Scott Burrows certified the Q2 2026 10-Q (quarter ended June 30, 2026) on August 4, 2026, per Sarbanes-Oxley Sections 302 and 906. Both officers affirm financial statements fairly present the company's condition, results, and cash flows; no material weaknesses, significant deficiencies, or fraud involving management disclosed. These are routine quarterly compliance certifications.
Why this rating
Boilerplate SOX certifications; standard quarterly filing requirement. No operational, financial, deal, or control-material changes reported here.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.